Home > Publications > Articles > Amicus Curiae Efforts to Reform Product Liability at the Food and Drug Administration: FDA’s Influence on Federal Preemption of Class III Medical Devices and Pharmaceuticals

Amicus Curiae Efforts to Reform Product Liability at the Food and Drug Administration: FDA’s Influence on Federal Preemption of Class III Medical Devices and Pharmaceuticals

Posted:
12/01/2005
Industries:
Life Sciences

In this article, Mark C. Levy, a Partner in the Litigation Department and resident in the Philadelphia office, discuss the use of amicus curiae briefs in relation to the Food and Drug Administration.

With permission from FDLI, to read the article, click the link below.